TWST Stock News & Catalysts – Twist Bioscience

FEATURED

Twist Bioscience to Present at Upcoming Investor Conferences

New

Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist

Summary

Nov 9, 2026, 8:00 AM ·Business Wire

RECENT

Why the Next Edge in Antibody Discovery May Be What Labs Remember

AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - For most of the history of antibody discovery, the hard part was producing candidates. Generative models, high-throughput assays

Nov 4, 2026, 8:15 AM ·Globe Newswire

Notice of Proposed Derivative Settlement: Twist Bioscience Corporation

Twist Bioscience Corporation (NASDAQ:TWST): UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION Lead Case No. 1:23-cv-01048-MN SUMMARY NOTICE OF

Nov 3, 2026, 4:05 PM ·Business Wire

Twist Bioscience Launches MRD Express with Rapid Turnaround Time

Turnaround time starting within one day Twist panel enables researchers to combine the sensitivity of tumor-informed MRD detection with the speed and simplicity of tumor-naïve MRD detection when developing their

Oct 29, 2026, 8:00 AM ·Business Wire

Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies

Enables high-throughput assessment of thousands of antibodies per day to support AI/ML-driven discovery workflows Turnaround time starting in as little as five days Twist Bioscience Corporation (NASDAQ:TWST), a

Oct 28, 2026, 8:00 AM ·Business Wire

Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026

Company to host conference call at 8:00 AM ETTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for the fiscal 2026 fourth

Oct 26, 2026, 8:00 AM ·Business Wire

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

Equity Insider News Commentary AUSTIN, Texas, Oct. 1, 2026 /CNW/ -- Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound

Oct 1, 2026, 12:11 PM ·PRNewswire

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

Antibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today

Sep 16, 2026, 8:00 AM ·Business Wire

Twist Bioscience to Present at Baird 2026 Global Healthcare Conference

Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience,

Sep 9, 2026, 8:00 AM ·Business Wire

AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030

AUSTIN, Texas, Sept. 3, 2026 /CNW/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug

Sep 3, 2026, 8:55 AM ·PRNewswire

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Corporation (NASDAQ:TWST) ("Twist"), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock

Aug 4, 2026, 11:45 PM ·Business Wire

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation (NASDAQ:TWST) ("Twist"), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common

Aug 4, 2026, 4:01 PM ·Business Wire

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a mid-cap growth and value biotech company, today announced that a total of

Aug 4, 2026, 8:00 AM ·Business Wire

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026. Visit the

Aug 3, 2026, 7:15 AM ·Business Wire

Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026

Company to host conference call at 8:00 AM ETTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 third

Jul 15, 2026, 8:00 AM ·Business Wire

Twist Bioscience Corporation TWST · News